Skip to main content
. 2022 Apr 5;119(15):e2122512119. doi: 10.1073/pnas.2122512119

Fig. 6.

Fig. 6.

In vivo ovarian suppression following treatment with MISR2 agonists. (A) Schematic representation of in vivo experiments in rats and Misr2 knockout mice injected daily from PND2 to PND12 and from PND3 to PND7, respectively, with gandotinib (40 mg/kg), SP600125 (45 mg/kg), CYC-116 (50 mg/kg), ruxolitinib (20 mg/kg), or vehicle control. (B) Representative H&E-stained sections of ovaries from PND2 rat pups treated once a day for 10 d with gandotinib (40 mg/kg), SP600125 (45 mg/kg), CYC-116 (50 mg/kg), ruxolitinib (20 mg/kg), or vehicle control (n = 8 per group), and (C) corresponding follicle counts (mean ± SEM, **P < 0.01, ***P < 0.005, ****P < 0.001). (D, E) Follicle counts in serial sections of PND3 Amhr2 knockout heterozygous (D) and homozygous (E) mice pup ovaries treated once a day for 4 d with gandotinib (40 mg/kg), SP600125 (45 mg/kg), CYC-116 (50 mg/kg), ruxolitinib (20 mg/kg), or vehicle control (n = 6 per group, mean ± SEM, **P < 0.01, ***P < 0.005, ****P < 0.001). PND7, postnatal day 7; PND12, postnatal day 12.